Amrinone

Amrinone (Inamrinone) is a positive inotropic-vasodilator agent. Amrinone is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. Amrinone is also an orally active, non-glycosidic and non-catecholamine cardiotonic agent[1][2][3].

Product Specifications

CAS Number

[60719-84-8]

Product Name Alternative

Inamrinone

UNSPSC

12352005

Hazard Statement

H301

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/amrinone.html

Purity

98.04

Solubility

DMSO : 16.67 mg/mL (ultrasonic)

Smiles

O=C1C(N)=CC(C2=CC=NC=C2)=CN1

Molecular Formula

C10H9N3O

Molecular Weight

187.20

Precautions

H301

References & Citations

[1]M Hachisu, et al. [Effects of Amrinone, an Inhibitor of c-AMP-specific Phosphodiesterases, on Neointimal Hyperplasia After Balloon Injury in Rats]. Nihon Yakurigaku Zasshi. 1998 Oct;112 (4) :267-74.|[2]A A Alousi, et al. The Beneficial Effect of Amrinone on Acute Drug-Induced Heart Failure in the Anaesthetised Dog. Cardiovasc Res. 1985 Aug;19 (8) :483-94.|[3]S Ichioka, et al. Clinical Use of Amrinone (A Selective Phosphodiesterase III Inhibitor) in Reconstructive Surgery. Plast Reconstr Surg. 2001 Dec;108 (7) :1931-7.|[4]T H LeJemtel, et al. Amrinone: A New Non-Glycosidic, Non-Adrenergic Cardiotonic Agent Effective in the Treatment of Intractable Myocardial Failure in Man. Circulation. 1979 Jun;59 (6) :1098-104.